國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Items for Author "Kang, YK"

Return to Browse by Author

Showing 30 items.

Collection	Date	Title	Relation
[陳立宗] 期刊論文	2013-06-21	A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma	-
[陳立宗] 期刊論文	2013-11	Management of gastric cancer in Asia: Resource-stratified guidelines	-
[陳立宗] 期刊論文	2013-12	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma	-
[陳立宗] 會議論文/會議摘要	2014-01	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib	-
[陳立宗] 期刊論文	2014-07-02	Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial	-
[陳立宗] 期刊論文	2016-08	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma	-
[陳立宗] 期刊論文	2016-10	Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor	-
[陳立宗] 會議論文/會議摘要	2017-02	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial	-
[陳立宗] 會議論文/會議摘要	2017-09	ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer	-
[陳立宗] 會議論文/會議摘要	2017-09	ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer	-
[陳立宗] 會議論文/會議摘要	2017-09	Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)	-
[陳立宗] 會議論文/會議摘要	2017-09	A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)	-
[陳立宗] 期刊論文	2017-10	Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review	-
[陳立宗] 期刊論文	2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial	-
[陳立宗] 會議論文/會議摘要	2018-02	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	-
[陳立宗] 會議論文/會議摘要	2018-05	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	-
[陳立宗] 會議論文/會議摘要	2018-09	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	-
[陳立宗] 期刊論文	2019-02	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4)	-
[陳立宗] 會議論文/會議摘要	2019-02	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2	-
[陳立宗] 期刊論文	2019-03	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens	-
[陳立宗] 期刊論文	2020-01	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer	-
[陳立宗] 會議論文/會議摘要	2020-02	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data	-
[陳立宗] 期刊論文	2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data	-
[陳立宗] 會議論文/會議摘要	2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	-
[陳立宗] 會議論文/會議摘要	2021-05	Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)	-
[陳立宗] 期刊論文	2021-07	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab	-
[陳立宗] 期刊論文	2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study	-
[陳立宗] 期刊論文	2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr	-
[陳立宗] 期刊論文	2022-04	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials	-
[陳立宗] 期刊論文	2024-08-20	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri	-

Loading...

Category

Year

Items for Author "Kang, YK"